Search results for "urea"
showing 10 items of 888 documents
What is individual in individualised instruction? Five storylines of meeting individual needs at school
2015
Abstract The purpose of this narrative case study was to examine the meanings and practices of individualised instruction narrated by two seventh-grade Finnish pupils with mild learning difficulties, their mothers, their special education teacher and researchers. The data comprise narrative interviews and field notes. The analysis showed that the narrators had various, even conflicting, experiences of individualisation, which was narrated through five storylines: individual needs as difficulties and limitations; individualisation as the ideal principle for inclusive education; individualisation as a bureaucratic procedure; individualised instruction as making room for emotions, and individu…
Synthesis of fluorine-18 labeled sulfonureas as ?-cell imaging agents
2001
Tolbutamide (1) and glyburide (7) are hypoglycemic drugs used to stimulate insulin secretion in type 2 diabetic patients. We have synthesized their fluorine-18 labeled analogs, 1-[(4-[ 18 F]fluorobenzenesulfonyl)]-3-butyl]urea (p-[ 18 F]fluorotolbutamide, 3a) and N-{4-[β-(2-[ 18 F]fluoroethoxybenzene carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (2-[ 18 F]fluoroethoxyglyburide, 6a) as β-cell imaging agents. Compound 3a was synthesized via two approaches: One-step synthesis via nucleophilic substitution of p-nitrotolbutamide (2) with K[ 18 F]/Kryptofix 2.2.2 in either CH 3 CN or DMSO gave a complicated mixture; a two-step synthesis via preparation and reaction of 4-[ 18 F]fluorobenzen…
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colore…
2020
International audience; BACKGROUND: Regorafenib significantly increases overall survival (OS) in patients with metastatic colorectal cancer previously treated but gives toxicities. OBJECTIVES: to assess the efficacy and safety of regorafenib at it's approved dose in the older population. PATIENTS AND METHODS: This multicenter single-arm phase II enrolled patients ≥70 years old after the failure of fluoropyrimidine-based chemotherapy, anti-VEGF, and anti-EGFR treatment. The primary endpoint was disease control rate (DCR) 2 months after initiation of regorafenib (160 mg/day, 3 weeks on/1 week off). RESULTS: Forty-three patients were enrolled, with a median age of 77 years. The 2 months DCR wa…
Chronic low level metribuzin exposure induces metabolic alterations in rats
2013
Abstract In this work we evaluated the in vivo effects of chronic metribuzin exposure at doses that mimic human exposure through diet. Male and female rats were fed a potato diet containing metribuzin at low doses (D1, 1.3 mg/kg or D2, 13 mg/kg) for 3 months. Plasma biochemical parameters (glucose, lipid, urea, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST)), as well as lipid and protein contents, markers of oxidative stress in different organs (liver, adipose tissue, muscle, intestine) were determined. Our results showed that exposure to metribuzin induced a significant reduction in body weight, food intake and adverse alterations in biochemical parameters suc…
A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes
2015
Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…
Blood urea nitrogen to creatinine ratio in acute heart failure: an old concept brought to reality?
2016
Renal dysfunction is one of the most important comorbidities in patients with chronic heart failure (HF) and frequently accentuated in the setting of acute HF (AHF).1 In either context, renal dysfunction has important clinical implications that deserve to be highlighted: (A) the added increase in risk of adverse clinical outcomes2 and (B) at greater degrees of renal failure, well evidenced therapies are lacking and current management remains mostly empirical.1 The pathophysiology of renal dysfunction in AHF is complex, multifactorial and not completely understood, which may potentially explain why patients with worsening renal function (WRF) show mixed clinical response and outcomes.1 An im…
Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring
2004
Summary Background : There are conflicting reports on the role of gastro-oesophageal reflux disease (GERD) and Helicobacter pylori infection in the aetiology of carditis. Aim : The role of reflux and H. pylori infection in causing carditis was assessed in 113 consecutive patients with GERD and in 25 controls. Methods : All subjects underwent endoscopy and pH test and carditis was diagnosed on biopsies taken across the squamocolumnar junction. Helicobacter pylori was assessed by histology and rapid urease test. GERD was diagnosed by endoscopic oesophagitis or abnormal pH test. Results : Carditis was detected in 53 of 71 GERD patients and in 15 of 20 controls. Among patients, 18 showed absent…
A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial
2004
Background & Aims: Antibiotic resistance is a major issue in anti– Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily f…
Aestivation Motifs Explain Hypertension and Muscle Catabolism in Experimental Chronic Renal Failure
2020
Chronic renal failure leads to muscle mass loss and hypertension, which according to textbook teaching occur secondary to an inability of the kidneys to excrete solutes and water. We found instead that rats with experimental chronic renal failure constantly lost body water, because their kidneys could not sufficiently concentrate the urine. Physiological adaptation to body water loss, termed aestivation, is an evolutionary conserved survival strategy that relies on complex physiologic-metabolic adjustment across multiple organs to prevent otherwise lethal dehydration. We show that rats with chronic renal failure utilize these ancient water conservation motifs to successfully stabilize their…
Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, ra…
2021
International audience; BACKGROUND: Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. METHODS: This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined …